{
  "kind": "treatment",
  "slug": "spravato-esketamine",
  "type": "interventional",
  "name": "Spravato (Esketamine)",
  "summary": "An FDA-approved intranasal esketamine treatment for treatment-resistant depression, administered under clinical supervision.",
  "description": "Spravato is the brand name for intranasal esketamine, an NMDA receptor antagonist approved by the FDA for adults with treatment-resistant depression (TRD) and depressive symptoms in major depressive disorder (MDD) with acute suicidal ideation or behavior. Administered in certified healthcare settings under a REMS (Risk Evaluation and Mitigation Strategy) program, Spravato offers rapid antidepressant effects, typically within hours to days, unlike conventional antidepressants that may take weeks.",
  "category": "interventional/pharmacological",
  "tags": ["esketamine", "spravato", "treatment-resistant depression", "MDD", "intranasal therapy"],

  "metadata": {
    "intervention_types": ["NMDA receptor antagonist", "Pharmacological"],
    "treatment_types": ["Interventional medication"],
    "categories": ["Psychiatry", "Mood Disorders"],
    "delivery_methods": ["Intranasal spray (clinic-based)"],
    "invasiveness_level": "Minimally invasive (non-surgical, supervised medication administration)",
    "equipment_required": false,
    "training_required": true,
    "age_groups": ["Adult"],
    "session_duration": "2–3 hours (including monitoring)",
    "treatment_duration": [
      "Acute induction phase: twice weekly for 4 weeks",
      "Maintenance phase: weekly or biweekly"
    ],
    "specialty_areas": ["Psychiatry", "Behavioral Health"]
  },

  "clinical_metadata": {
    "primary_indications": [
      "Treatment-resistant depression (TRD)",
      "Major depressive disorder (MDD) with acute suicidal ideation"
    ],
    "conditions_treated": ["Depression", "Suicidality (MDD-related)"],
    "off_label_uses": [
      "Bipolar depression (studies ongoing)",
      "Anxiety disorders (investigational)"
    ],
    "contraindications": [
      "Aneurysmal vascular disease",
      "Intracerebral hemorrhage",
      "Hypersensitivity to esketamine or ketamine"
    ],
    "safety_profile": "Requires in-clinic monitoring for sedation, dissociation, increased blood pressure, and risk of misuse. Administered only in REMS-certified settings.",
    "evidence_level": "Strong (multiple RCTs and FDA approval for TRD and acute suicidality in MDD).",
    "research_support": "Robust clinical trials demonstrate efficacy in rapid reduction of depressive symptoms, especially in TRD.",
    "invasiveness": "Minimally invasive",
    "efficacy_rating": {
      "treatment_resistant_depression": 5,
      "acute_suicidal_ideation": 4
    }
  },

  "sections": [
    {
      "type": "indications",
      "items": [
        "{link:depression}",
        "{link:major-depressive-disorder}",
        "{link:treatment-resistant-depression}",
        "{link:suicidality}"
      ]
    },
    {
      "type": "mechanism",
      "text": "Esketamine is an NMDA receptor antagonist that enhances glutamatergic neurotransmission, increases synaptogenesis, and modulates brain circuits implicated in mood regulation. Unlike SSRIs, it works through glutamate pathways and provides rapid symptom relief."
    },
    {
      "type": "protocol",
      "preparation": "Baseline assessment of psychiatric and medical history; blood pressure monitored pre- and post-dose.",
      "procedure": [
        "Administered intranasally under supervision in a certified clinic.",
        "Induction phase: twice weekly dosing for 4 weeks.",
        "Maintenance phase: weekly or biweekly dosing, individualized."
      ],
      "frequency": "Induction: 2 times per week; Maintenance: 1–2 times per month.",
      "duration": "Acute and maintenance treatment phases may extend long-term depending on response."
    },
    {
      "type": "expected_outcomes",
      "immediate": ["Rapid improvement in depressive symptoms within 24–48 hours"],
      "short_term": ["Reduction in suicidal ideation", "Improved mood and functioning"],
      "long_term": ["Sustained remission of depressive episodes with maintenance therapy"]
    },
    {
      "type": "side_effects",
      "common": ["Dissociation", "Dizziness", "Sedation", "Nausea", "Increased blood pressure"],
      "uncommon": ["Urinary tract symptoms", "Perceptual disturbances"],
      "rare": ["Dependence or misuse risk (lower than IV ketamine)"]
    },
    {
      "type": "patient_selection",
      "ideal_candidates": [
        "Adults with treatment-resistant depression",
        "Patients with MDD and acute suicidal ideation"
      ],
      "screening_required": [
        "Blood pressure monitoring",
        "Substance use history",
        "Cardiovascular risk assessment"
      ]
    },
    {
      "type": "training_requirements",
      "practitioner": [
        "Psychiatrists",
        "Nurse practitioners",
        "Physician assistants (in REMS-certified centers)"
      ],
      "facility": [
        "REMS-certified outpatient clinic",
        "In-clinic observation for at least 2 hours post-dose"
      ]
    },
    {
      "type": "research_evidence",
      "studies": [
        "Multiple Phase III RCTs demonstrated rapid and significant reductions in depressive symptoms in TRD.",
        "FDA approval in 2019 based on robust clinical data.",
        "Studies show sustained benefits when combined with oral antidepressants."
      ],
      "limitations": "Requires ongoing maintenance dosing, high cost, potential for dissociation and misuse."
    },
    {
      "type": "cost_considerations",
      "typical_session_cost": "$600–$900 per administration (excluding monitoring and facility fees).",
      "total_treatment_cost": "Thousands per month depending on frequency.",
      "insurance_coverage": "Increasingly covered for TRD with prior authorization.",
      "cost_effectiveness": "Cost-effective in reducing hospitalizations and suicidality for TRD."
    },
    {
      "type": "integration_support",
      "concurrent_therapies": [
        "Concurrent oral antidepressants (required by FDA label)",
        "Psychotherapy",
        "Lifestyle interventions"
      ],
      "lifestyle_recommendations": [
        "Avoid driving until the next day post-dose",
        "Follow-up visits for ongoing mood assessment"
      ]
    },
    {
      "type": "special_populations",
      "pediatric": "Not approved; safety not established.",
      "elderly": "May be used with caution due to cardiovascular effects.",
      "pregnancy": "Not recommended (insufficient safety data).",
      "comorbidities": "Monitor carefully in cardiovascular disease or substance use history."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Administered only in certified clinics under REMS program.",
        "Not a first-line antidepressant; indicated after inadequate response to ≥2 antidepressants.",
        "Often combined with oral SSRIs/SNRIs for sustained effect."
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Daly EJ, et al. Efficacy and safety of intranasal esketamine for treatment-resistant depression. JAMA Psychiatry. (2019).",
          "url": "https://pubmed.ncbi.nlm.nih.gov/30821918/"
        },
        {
          "label": "FDA. Spravato (esketamine) Nasal Spray Label. (2019).",
          "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243lbl.pdf"
        },
        {
          "label": "Papakostas GI, et al. Esketamine nasal spray for rapid reduction of depressive symptoms. Int J Neuropsychopharmacol. (2020).",
          "url": "https://pubmed.ncbi.nlm.nih.gov/32227061/"
        }
      ]
    }
  ],

  "seo": {
    "title": "Spravato (Esketamine) | FDA-Approved Nasal Spray for Depression",
    "description": "Spravato (esketamine) is an FDA-approved intranasal treatment for treatment-resistant depression and MDD with suicidality. Learn about mechanism, outcomes, side effects, and clinical use."
  }
}
